WuXi AppTec
A global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
Launch date
Employees
Market cap
CAD21.3b
Enterprise valuation
CAD19.9b (Public information from Sep 2024)
Share price
CNY40.91 603259.SS
Shanghai Shanghai (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 16.5b | 22.9b | 39.4b | 40.3b | 39.6b | 43.3b | 48.2b |
| % growth | 28 % | 39 % | 72 % | 3 % | (2 %) | 9 % | 11 % |
| EBITDA | 4.6b | 7.2b | 12.8b | 14.7b | 14.0b | 15.5b | 16.0b |
| % EBITDA margin | 28 % | 32 % | 32 % | 37 % | 35 % | 36 % | 33 % |
| Profit | 3.0b | 5.1b | 8.8b | 9.6b | 9.6b | 10.7b | 11.2b |
| % profit margin | 18 % | 22 % | 22 % | 24 % | 24 % | 25 % | 23 % |
| EV / revenue | 19.3x | 14.9x | 5.9x | 5.1x | 2.6x | 2.2x | 1.9x |
| EV / EBITDA | 69.4x | 47.3x | 18.3x | 14.0x | 7.3x | 6.2x | 5.6x |
| R&D budget | 693m | 942m | 1.6b | 1.4b | - | - | - |
| R&D % of revenue | 4 % | 4 % | 4 % | 4 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$2.2m | Series A | ||
| N/A | $2.2m | Series A | |
N/A | Series B | ||
$17.3m | Series C | ||
$63.0m | Post IPO Equity | ||
| N/A | N/A | Post IPO Equity | |
$1.5b | Debt | ||
| N/A | $1.0b Valuation: $10.2b 9.6x EV/LTM Revenues 35.9x EV/LTM EBITDA | IPO | |
* | N/A | $1.0b | Post IPO Equity |
| Total Funding | CAD29.6m | ||
Related Content
Recent News about WuXi AppTec
EditInvestments analysisEdit
ACQUISITION by WuXi AppTec Jan 2017
exited
